Targeted chemoembolization of tumors with poly(2-hydroxyethyl methacrylate) particles.
Thirty-four patients suffering from various kinds of tumors, including metastasis, were treated by selective embolization with both spherical and cylindrical poly(2-hydroxyethyl methacrylate) [poly(HEMA)] particles and topical chemotherapy. Treatment of a patient with carcinoid metastases in the liver is discussed. Immediately after embolization, 5-fluorouracil, and later, doxorubicin and Lipiodol, were selectively infused into the tumorous tissue for approximately 1 week. Patient received four cycles of this infusion. Chemoembolization proceeded against the background of anticoagulant therapy using small doses of heparin or its low-molecular-weight analogue, dalteparin. This was followed by transcutaneous transhepatic portography and embolization. Finally, the tumor-feeding artery and portal vein were sealed by a hydrogel. After 1.5 months, the affected liver lobe was resected. Although 4 years from the beginning of treatment, the patient is still alive. Embolization with poly(HEMA) hydrogel particles in conjunction with an anticancer drug infusion via catheter is recommended as an efficient method of tumor treatment. The therapeutic effect has been shown to be a function of ischemia and slow local infusion of drug into the tumor, and systemic drug levels can be kept low.
Horák
D
D
Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague.
Guseinov
E
E
Vishnevskii
V
V
Adamyan
A
A
Kokov
L
L
Tsvirkun
V
V
Tchjao
A
A
Titova
M
M
Skuba
N
N
Trostenyuk
N
N
Gumargalieva
K
K
D000925:Anticoagulants / Q000627:therapeutic use; D002276:Carcinoid Tumor / Q000401:mortality / Q000556:secondary / Q000628:therapy; D016461:Chemoembolization, Therapeutic / Q000379:methods; D003110:Colonic Neoplasms / Q000401:mortality / Q000628:therapy; D017985:Dalteparin / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005472:Fluorouracil / Q000008:administration & dosage*; D006394:Hemangiosarcoma / Q000401:mortality / Q000556:secondary / Q000628:therapy; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D011073:Polyamines; D011102:Polyhydroxyethyl Methacrylate / Q000031:analogs & derivatives*; D012004:Rectal Neoplasms / Q000401:mortality / Q000628:therapy; D015996:Survival Rate
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D011073:Polyamines; C056971:poly(2-hydroxyethyl methacrylate)-polyamine graft copolymer; D011102:Polyhydroxyethyl Methacrylate; D004317:Doxorubicin; D017985:Dalteparin; D005472:Fluorouracil